Latest Ratios: P/E Ratio -53.7x · EV/EBITDA N/A · ROE -27.8%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.4B | $2.5B | $883M | $707M | $1.1B | $3.9B | $7.8B | $3.7B | — | — |
| Enterprise Value | $3.6B | $2.7B | $924M | $741M | $1.1B | $3.9B | $7.7B | $3.7B | — | — |
| P/E Ratio → | -53.74 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 12.11 | 8.90 | 4.93 | 4.15 | 5.88 | 25.52 | 78.86 | 43.73 | — | — |
| P/B Ratio | 14.13 | 10.95 | 4.36 | 2.29 | 2.35 | 6.52 | 10.44 | 6.51 | — | — |
| P/FCF | — | — | — | — | — | — | — | 19.16 | — | — |
| P/OCF | — | — | — | — | — | — | — | 18.11 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 9.65 | 5.16 | 4.35 | 5.97 | 25.34 | 78.71 | 43.03 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | 18.85 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 74.2% | 74.2% | 59.7% | 55.6% | 68.7% | 68.1% | 77.1% | 73.8% | 64.7% | 59.2% |
| Operating Margin | -20.6% | -20.6% | -90.8% | -133.3% | -108.0% | -135.4% | -155.3% | -92.1% | -89.4% | -115.7% |
| Net Profit Margin | -21.5% | -21.5% | -89.1% | -132.3% | -108.0% | -134.3% | -148.6% | -80.6% | -83.4% | -111.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -27.8% | -27.8% | -62.5% | -58.3% | -37.5% | -30.8% | -22.3% | -43.8% | — | — |
| ROA | -11.3% | -11.3% | -26.6% | -29.7% | -22.5% | -20.3% | -14.4% | -11.0% | -13.4% | -11.8% |
| ROIC | -12.6% | -12.6% | -41.6% | -41.3% | -28.4% | -24.0% | -18.5% | -15.5% | -14.9% | — |
| ROCE | -13.2% | -13.2% | -32.0% | -34.4% | -25.7% | -23.0% | -16.6% | -13.7% | -15.3% | -13.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.25 | 1.25 | 0.44 | 0.32 | 0.23 | 0.18 | 0.15 | 0.06 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.93 | 0.20 | 0.11 | 0.04 | -0.05 | -0.02 | -0.11 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | -0.31 | — | — |
| Interest Coverage | -4.05 | -4.05 | -12.78 | -15.33 | -46.28 | — | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.34 | 3.34 | 2.89 | 4.66 | 5.12 | 3.54 | 6.91 | 7.82 | 7.93 | 9.77 |
| Quick Ratio | 3.23 | 3.23 | 2.81 | 4.50 | 4.99 | 3.37 | 6.78 | 7.71 | 7.58 | 9.54 |
| Cash Ratio | 2.52 | 2.52 | 2.27 | 3.94 | 4.54 | 3.10 | 6.54 | 7.37 | 7.24 | 9.15 |
| Asset Turnover | — | 0.54 | 0.33 | 0.26 | 0.22 | 0.17 | 0.09 | 0.09 | 0.17 | 0.11 |
| Inventory Turnover | 7.27 | 7.27 | 8.54 | 5.23 | 4.01 | 2.56 | 1.60 | 2.46 | 2.51 | 3.27 |
| Days Sales Outstanding | — | 66.37 | 85.11 | 81.39 | 78.90 | 41.17 | 37.27 | 54.39 | 31.52 | 52.99 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | 5.2% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $152M | $147M | $144M | $143M | $140M | $131M | $124M | $105M | $105M |
Limited liquidity and dilution
Based on reported figures, Adaptive Biotechnologies trades at a price-to-sales multiple of 12.11, which appears elevated given the company's persistent operating losses and the inherent volatility of its milestone-dependent revenue streams compared to more established diagnostic peers in the liquid biopsy and molecular testing space.
The current P/S multiple suggests that investors are pricing in significant future growth from the Immune Medicine platform rather than the current clinical diagnostic business. This valuation warrants caution, as it implies a high hurdle for execution that the company has yet to consistently meet in its historical financial performance.
As reported in financial statements, the company's ROIC has remained consistently negative over the last ten quarters, bottoming at -14.9% in 2023Q4, which indicates that the firm is currently destroying shareholder value rather than compounding capital through its specialized immune-repertoire sequencing and diagnostic service offerings.
The inability to generate positive returns on invested capital suggests that the high fixed-cost structure of the laboratory infrastructure is not yet being offset by sufficient clinical test volumes. Investors should monitor whether the recent strategic restructuring can improve asset utilization enough to move ROIC toward a break-even threshold.
According to recent SEC filings, the company's cash conversion cycle has fluctuated significantly, peaking at 120 days in 2023Q4 before moderating to 75 days in 2026Q1, reflecting ongoing challenges in managing receivables and inventory turnover within the complex clinical diagnostic and pharmaceutical partnership service models.
The variability in the cash conversion cycle suggests that the company lacks the operational leverage to optimize its working capital efficiently. This inefficiency places additional pressure on the firm's limited cash reserves, as capital remains tied up in the diagnostic testing pipeline for extended periods.
Based on the most recent quarterly data, the company's current ratio of 3.35 provides a superficial appearance of liquidity, yet the underlying cash position of $70.5M against a trailing twelve-month operating loss exceeding $50M suggests a vulnerable financial position that necessitates careful monitoring of future financing needs.
While the current ratio appears healthy, it is heavily influenced by non-cash assets, masking the reality of the company's cash burn. The firm's reliance on external capital to fund operations appears increasingly risky if the clinical diagnostic business does not achieve self-sustaining cash flow in the near term.
The price-to-sales ratio is frequently misapplied to Adaptive Biotechnologies, as it fails to distinguish between high-margin, recurring clinical diagnostic revenue and lumpy, non-recurring milestone payments from pharmaceutical partnerships, which can significantly distort the perceived growth trajectory and underlying quality of the company's revenue base.
Analysts should instead focus on core diagnostic volume growth and adjusted operating margins to better assess the company's true earning power. Relying on P/S multiples obscures the significant operational overhead and stock-based compensation that continue to weigh on the firm's path to profitability.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ADPT stock.
Adaptive Biotechnologies Corporation's current P/E ratio is -53.7x. This places it at the 50th percentile of its historical range.
Adaptive Biotechnologies Corporation's return on equity (ROE) is -27.8%. The historical average is -40.4%.
Based on historical data, Adaptive Biotechnologies Corporation is trading at a P/E of -53.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Adaptive Biotechnologies Corporation has 74.2% gross margin and -20.6% operating margin.